The IV record
IV NAD therapy and the fate of NAD+
The IV story has a surprisingly long past. Its chemistry, clinical reports and compounding risks deserve to be examined together.
The 1961 addiction report
The date was the surprise for me. Braidy and colleagues’ review reaches back to O’Hollaren’s 1961 report of 104+ addiction cases, with reported reductions in cravings and withdrawal symptoms. This history predates the current wellness conversation.
Age gives a report historical interest. A controlled comparison gives it a better chance of identifying an effect. The review itself calls for rigorous randomized trials and notes that IV NAD+ remains unapproved by FDA. I take that call seriously; the elapsed time makes the unanswered question more pressing.
The fifty-case series
A later report followed 50 people with treatment-resistant substance use disorder. IV NAD+ was given alongside enkephalinase inhibition, another intervention. Craving, anxiety and depression scores decreased. In a 40-patient subset, 100% of urine samples were negative for illicit substances midway through treatment.
The missing untreated comparison and the combined treatment limit attribution. The observed improvement matters, but this design cannot tell us how much NAD+ contributed or how durable the change was. Linking these addiction cases to everyday focus exhausts my patience.
Extracellular NAD in skin cells
The Aleo experiment in human skin fibroblasts is small-scale chemistry with an important subject: what happens to NAD outside cells. Surface enzymes degraded it into smaller products. Adenosine was the principal breakdown product taken up and converted to intracellular ATP.
These were cultured human cells, rather than people receiving infusions. I value the finding for the question it raises about intact entry. A drip entering a vein still leaves the cellular handling to be explained. This experiment supplies no human plasma-clearance curve or injection half life.
Infusion symptoms and compounding
The IV review discusses infusion-related chest or abdominal discomfort, flushing and nausea, with symptoms eased by slowing or stopping the infusion. The timing and duration of symptoms were incompletely reported.
Compounding brings a separate quality question. Elevated bacterial endotoxin, a contaminant that can cause serious injury or death, prompted a Class I FDA recall of a compounded NAD+ injection. That event concerns a recalled preparation; it gives a concrete reason to take preparation quality seriously.
Compounded NAD+ medicines are not FDA-approved. No FDA-approved IV NAD+ treatment exists for the illnesses discussed here. A prescription decision and drug approval answer different questions.
Anecdotal reports
People may describe a clearer head or different energy after a drip. Such personal accounts are anecdotes, and they do not count as clinical evidence. They cannot identify the active cause of a change, establish its duration or reveal how other people would fare.
My confidence grows where the published IV review calls for controlled trials, even as it recounts the history and preliminary reports. The oral precursor trials offer stronger comparisons while still leaving large health claims unsettled.